Research Analysts Set Expectations for Immunome Q1 Earnings

Immunome, Inc. (NASDAQ:IMNM) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Immunome in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings per share of ($0.94) for the quarter. The consensus estimate for Immunome’s current full-year earnings is ($2.21) per share. Leerink Partnrs also issued estimates for Immunome’s Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($1.02) EPS, Q4 2025 earnings at ($1.07) EPS, FY2025 earnings at ($4.06) EPS, FY2026 earnings at ($4.17) EPS and FY2027 earnings at ($3.80) EPS.

IMNM has been the topic of a number of other research reports. Wedbush reissued an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a research note on Monday, January 13th. Stephens assumed coverage on shares of Immunome in a report on Friday, November 8th. They set an “overweight” rating and a $30.00 price objective on the stock. Finally, Piper Sandler lowered their price objective on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $28.60.

Immunome Price Performance

NASDAQ IMNM opened at $11.22 on Monday. The stock’s 50 day simple moving average is $11.15 and its 200 day simple moving average is $12.57. Immunome has a one year low of $8.97 and a one year high of $30.96. The firm has a market cap of $895.13 million, a PE ratio of -1.38 and a beta of 1.90.

Institutional Trading of Immunome

A number of institutional investors and hedge funds have recently modified their holdings of IMNM. FMR LLC grew its holdings in Immunome by 0.3% during the third quarter. FMR LLC now owns 4,224,700 shares of the company’s stock valued at $61,765,000 after purchasing an additional 13,757 shares during the period. Janus Henderson Group PLC grew its holdings in shares of Immunome by 10.3% in the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock valued at $50,971,000 after buying an additional 324,614 shares during the period. Geode Capital Management LLC increased its position in shares of Immunome by 13.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock valued at $17,657,000 after buying an additional 144,557 shares in the last quarter. Victory Capital Management Inc. raised its stake in Immunome by 48.1% during the 3rd quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock worth $10,684,000 after buying an additional 237,497 shares during the period. Finally, Point72 Asset Management L.P. lifted its holdings in Immunome by 22.2% during the third quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company’s stock worth $6,881,000 after acquiring an additional 85,580 shares in the last quarter. 44.58% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Immunome news, insider Robert Lechleider bought 15,805 shares of the company’s stock in a transaction on Thursday, November 21st. The stock was bought at an average price of $9.48 per share, for a total transaction of $149,831.40. Following the transaction, the insider now owns 15,805 shares of the company’s stock, valued at approximately $149,831.40. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Clay B. Siegall purchased 66,057 shares of Immunome stock in a transaction dated Thursday, November 21st. The stock was bought at an average price of $9.54 per share, for a total transaction of $630,183.78. Following the completion of the transaction, the chief executive officer now directly owns 485,693 shares in the company, valued at $4,633,511.22. The trade was a 15.74 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders bought 252,862 shares of company stock valued at $2,140,545. 8.60% of the stock is currently owned by insiders.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.